Medline is the largest provider of medical-surgical products and supply chain solutions in the US. The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families—including front-line care, surgical solutions, and laboratory and diagnostics—as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.
Last trade$38.08
Day change-$1.09 (-2.78%)
Day range$37.78 – $39.37
Volume4,892,445
Market cap$34.42B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$34.42B
Price / earnings
88.93×
Price / book
2.92×
Price / sales
1.5×
EV / sales
1.95×
EV / EBITDA
21.42×
Profitability
Earnings per share
$0.44
Return on assets
0.96%
Return on equity
3.28%
Dividend yield
0.35%
Liquidity and leverage
Debt / equity
1.07×
Current ratio
4.04×
Quick ratio
2.51×
Cash ratio
0.74×
Cash flow
Price / cash flow
12.34×
Price / free cash flow
14.71×
Free cash flow
$2.34B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MDLN, quarterly periods
Line item
Q3 FY2026 Sep 26, 2026
Q2 FY2026 Jun 27, 2026
Q1 FY2026 Mar 28, 2026
Q4 FY2025 Dec 31, 2025
Revenue
$7.86B
$7.69B
$7.35B
—
Cost of revenue
$5.93B
$5.47B
$5.51B
$0
Gross profit
$1.93B
$2.22B
$1.84B
—
Selling, general and administrative
$1.26B
$1.3B
$1.23B
—
Research and development
$0
$0
$0
—
Total operating expenses
$1.43B
$1.82B
$1.42B
—
Operating income
$500M
$395M
$422M
—
Interest expense
-$165M
-$119M
-$136M
—
Income before taxes
$386M
$235M
$291M
—
Income taxes
$68M
$96M
$52M
—
Net income
$318M
$139M
$239M
—
Net income attributable to common shareholders
$198M
$60M
$129M
—
EBITDA
$759M
$651M
$676M
$0
Basic earnings per share
$0.23
$0.07
$0.16
—
Diluted earnings per share
$0.22
$0.07
$0.16
—
Recent news
Company coverage with links to the original publishers.
Pomerantz LLP is investigating Medline Inc. for potential securities fraud following an FDA warning letter in June 2026 detailing significant manufacturing violations. The company's stock fell 7.16% on the FDA announcement and an additional 12.79% in August when Medline disclosed that remediation efforts resulted in earnings losses.
Law firm Bragar Eagel & Squire is investigating Medline Inc. for potential securities law violations following FDA warning letters regarding manufacturing practice violations. The company's stock declined 7.2% on June 2, 2026 after FDA warnings and another 12.8% on August 5, 2026 after the company disclosed earnings losses from remediation efforts including product recalls.
Pomerantz LLP is investigating Medline Inc. for potential securities fraud following an FDA warning letter in June 2026 detailing significant manufacturing violations. The company's stock fell 7.16% on the FDA announcement and another 12.79% in August when Medline disclosed that remediation efforts resulted in earnings losses.
Law firm Kirby McInerney LLP is investigating Medline Inc. for potential federal securities law violations following an FDA warning letter in June 2026 detailing significant manufacturing practice violations. The company's stock declined 7.2% on the FDA announcement and another 12.8% in August after Medline disclosed earnings losses from remediation efforts including product recalls.
Kessler Topaz Meltzer & Check, LLP is investigating potential securities law violations by Medline Inc. following significant FDA violations related to manufacturing quality standards and microbial contamination. The company's stock fell over 7% after the FDA warning letter and dropped an additional 12% following disappointing Q2 results and lowered full-year guidance.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.